The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.
There are many ongoing advances in the management of high risk and locally advanced prostate cancer, including concepts of systemic therapy intensification and de-escalation, dose escalation, and the use of biomarkers.
This program is designed to address the needs of a community practice physician and includes disease site reviews, interactive case-based discussions, a strategic dialogue with the ASTRO CEO and a radiation oncology practice overview.
This activity will evaluate contouring principles for patients with genitourinary malignancies and includes discussion about prostate cancers (definitive and post-operative) and bladder cancer.
The content was originally presented and recorded at the 2026 ASTRO Annual Refresher Course
Use of SABR for selected patients with oligoprogressive (OP) prostate cancer and renal cell carcinoma (RCC) has been shown to have the potential to improve progression-free survival, extend the time to developing new metastatic lesions, and delay time to starting next systemic therapy without add
There are many ongoing advances in the management of high risk and locally advanced prostate cancer, including concepts of systemic therapy intensification and de-escalation, dose escalation, and the use of biomarkers.
There are many evidence-based recommendations for nutrition and lifestyle in prostate cancer. Failure to counsel patients on nutrition and lifestyle leads to lower quality of care.
The management of bladder cancer is evolving across the spectrum of disease and stage and this educational activity is extremely valuable to the ASTRO membership.
Local therapies are increasingly being utilized in the treatment of oligometastatic prostate cancer. This webinar aims to review aspects of management and treatment of oligometastatic prostate cancer including discussions of contouring and plan evaluation.
This activity brings together an international panel and multidisciplinary expertise to discuss the emerging role of SABR to the primary in renal cell carcinoma (RCC).
Facebook
X
LinkedIn
Forward
